A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Merck Sharp & Dohme LLC
PMV Pharmaceuticals, Inc
AstraZeneca
Genmab
Eikon Therapeutics
Seagen Inc.
Tizona Therapeutics, Inc
IDEAYA Biosciences
Merck Sharp & Dohme LLC
Sichuan Baili Pharmaceutical Co., Ltd.
Eli Lilly and Company
Seagen Inc.
Sairopa B.V.
Eli Lilly and Company
Merck Sharp & Dohme LLC
Tempest Therapeutics
Merck Sharp & Dohme LLC
Eisai Inc.
Merck Sharp & Dohme LLC
Carisma Therapeutics Inc
NextCure, Inc.
Five Prime Therapeutics, Inc.
NETRIS Pharma
Pliant Therapeutics, Inc.
Corvus Pharmaceuticals, Inc.
Xencor, Inc.
Incyte Corporation
Incyte Corporation
Eisai Inc.